Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Franziska Briest"'
Autor:
Claus von Hessert-Vaudoncourt, Sara Lelek, Christina Geisler, Teresa Hartung, Vanessa Bröker, Franziska Briest, Liliana Mochmann, Fabian Jost-Brinkmann, Dagmar Sedding, Joana Benecke, Helma Freitag, Sebastian Wolfshöfer, Hedwig Lammert, Svenja Nölting, Michael Hummel, Jörg Schrader, Patricia Grabowski
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Somatostatin analogues (SSAs) are commonly used in the treatment of hormone hypersecretion in neuroendocrine tumors (NETs), however the extent to which they inhibit proliferation is much discussed.Objective: We studied the antiprolifera
Externí odkaz:
https://doaj.org/article/a407b702dbba487e9691d99b0851500c
Autor:
Franziska Briest, Eva J. Koziolek, Jakob Albrecht, Fränze Schmidt, Monique R. Bernsen, Joost Haeck, Anja A. Kühl, Dagmar Sedding, Teresa Hartung, Samantha Exner, Martina Welzel, Christian Fischer, Carsten Grötzinger, Winfried Brenner, Richard P. Baum, Patricia Grabowski
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 1, Pp 80-98 (2021)
Background: Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might
Externí odkaz:
https://doaj.org/article/ae7137f1c25a44b7a686f53aa5278365
Autor:
Antonia Busse, Liliana H. Mochmann, Christiane Spenke, Ruza Arsenic, Franziska Briest, Korinna Jöhrens, Hedwig Lammert, Bence Sipos, Anja A. Kühl, Ralph Wirtz, Marianne Pavel, Michael Hummel, Daniel Kaemmerer, Richard P. Baum, Patricia Grabowski
Publikováno v:
Cancers, Vol 12, Iss 11, p 3448 (2020)
Checkpoint inhibitors have shown promising results in a variety of tumors; however, in neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), low response rates were reported. We aimed herein to investigate the tumor immune microenvironment
Externí odkaz:
https://doaj.org/article/bf11acb18ad8481e8eda94c3873c6036
Autor:
Svenja Nölting, Jakob Rentsch, Helma Freitag, Katharina Detjen, Franziska Briest, Markus Möbs, Victoria Weissmann, Britta Siegmund, Christoph J Auernhammer, Elke Tatjana Aristizabal Prada, Michael Lauseker, Ashley Grossman, Samantha Exner, Christian Fischer, Carsten Grötzinger, Jörg Schrader, Patricia Grabowski, GERMAN NET-Z study group
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182852 (2017)
BACKGROUND/AIMS:The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α inhibition by the novel agent BYL719 on cell viability
Externí odkaz:
https://doaj.org/article/d90eb6998c164c8c907816964c638484
Autor:
Mareike Frick, Franziska Briest, Frederik Damm, Antje Maluck-Böttcher, Cornelius Hennch, Friederike Christen, Kaja Hoyer, Raphael Hablesreiter, Annett Madadi, Angela Segler, Lars Bullinger
Publikováno v:
Leukemia. 36:1102-1110
To investigate clonal hematopoiesis associated gene mutations in vitro and to unravel the direct impact on the human stem and progenitor cell (HSPC) compartment, we targeted healthy, young hematopoietic progenitor cells, derived from umbilical cord b
Autor:
Uwe Pelzer, Hanno Riess, Tetsuichi Yoshizato, Frederik Damm, Franziska Briest, Seishi Ogawa, Nobuyuki Kakiuchi, Yusuke Shiozawa, Yoshikage Inoue, M. Sinn, Kenichi Yoshida, Sven Bischoff, Jana Käthe Striefler, Yuichi Shiraishi, Michael Hummel, Lars Bullinger, Kaja Hoyer, Philipp Lohneis, Olga Blau, R. Hablesreiter, Friederike Christen, Hein Putter, U. Keilholz
Publikováno v:
EBioMedicine
EBioMedicine, Vol 66, Iss, Pp 103327-(2021)
EBioMedicine, 66. ELSEVIER
EBioMedicine, Vol 66, Iss, Pp 103327-(2021)
EBioMedicine, 66. ELSEVIER
Background: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treat-ment approaches. Addition of the
Autor:
Anja A. Kühl, Monique R. Bernsen, Winfried Brenner, M. Welzel, Richard P. Baum, Samantha Exner, Eva J. Koziolek, Jakob Albrecht, Dagmar Sedding, Patricia Grabowski, Christian Fischer, Fränze Schmidt, Teresa Hartung, Joost C. Haeck, Franziska Briest, Carsten Grötzinger
Publikováno v:
Neoplasia (New York, N.Y.)
BASE-Bielefeld Academic Search Engine
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 1, Pp 80-98 (2021)
Neoplasia (United States), 23(1), 80-98
BASE-Bielefeld Academic Search Engine
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 1, Pp 80-98 (2021)
Neoplasia (United States), 23(1), 80-98
Background: Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b0fcaaba5da9ca61e63d327232b0b4
http://www.scopus.com/inward/record.url?scp=85096683387&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85096683387&partnerID=8YFLogxK
Autor:
Richard P. Baum, Korinna Jöhrens, Liliana H Mochmann, Ralph M. Wirtz, Michael Hummel, Franziska Briest, Anja A. Kühl, Bence Sipos, Ruza Arsenic, Marianne Pavel, Patricia Grabowski, Antonia Busse, Daniel Kaemmerer, Hedwig Lammert, Christiane Spenke
Publikováno v:
Cancers, Vol 12, Iss 3448, p 3448 (2020)
Cancers
Volume 12
Issue 11
Cancers
Volume 12
Issue 11
Checkpoint inhibitors have shown promising results in a variety of tumors
however, in neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), low response rates were reported. We aimed herein to investigate the tumor immune microenviron
however, in neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), low response rates were reported. We aimed herein to investigate the tumor immune microenviron
Autor:
Sebastian Wolfshöfer, Adrian C Lock, Daniel Kaemmerer, Ralph M Wirtz, Franziska Briest, Sven P Haugvik, Malte Buchholz, Anja Rinke, Ruza Arsenic, Marianne Pavel, Dieter Hörsch, Arend Koch, Patricia Grabowski
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA043-LBA043
Medical therapeutic options for the treatment of well-differentiated pancreatic neuroendocrine neoplasms (pNENs) include the mTOR pathway inhibitor everolimus (in combination with 5-Fluorouracil). Criteria to assess prognosis in pNEN patients are sti
Autor:
Friederike Christen, Britta Siegmund, Irina Grass, Franziska Briest, Florentine Lewens, Sara Iwaszkiewicz, Patricia Grabowski, Helma Freitag
Publikováno v:
Neuroendocrinology. 105:90-104
Background: The characteristic clinical heterogeneity and mostly slow-growing behavior of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) cause problems in finding appropriate treatments. Thus, the current therapy options are not satisfact